ad image

Phase 3 TOLEDO Study

1 / 1
Britannia Pharmaceuticals
Phase 3 Study

Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson's Disease

Britannia Pharmaceuticals

PR-M08-18-NI-043Aug 13, 2018
1 / 1